Shanghai Hile Bio-tech - Asset Resilience Ratio

Latest as of September 2025: 8.89%

Shanghai Hile Bio-tech (603718) has an Asset Resilience Ratio of 8.89% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Shanghai Hile Bio-tech balance sheet liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥160.28 Million

≈ $23.45 Million USD Cash + Short-term Investments

Total Assets

CN¥1.80 Billion

≈ $263.87 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2015–2024)

This chart shows how Shanghai Hile Bio-tech's Asset Resilience Ratio has changed over time. See 603718 total equity for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Shanghai Hile Bio-tech's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 603718 market cap.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥160.28 Million	8.89%
Total Liquid Assets	CN¥160.28 Million	8.89%

Asset Resilience Insights

Limited Liquidity: Shanghai Hile Bio-tech maintains only 8.89% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Shanghai Hile Bio-tech Industry Peers by Asset Resilience Ratio

Compare Shanghai Hile Bio-tech's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Argen-X F:1AE	Biotechnology	25.67%
Tubize-Fin BR:TUB	Biotechnology	0.05%
BrightGene Bio Medical Technology C SHG:688166	Biotechnology	1.00%
Dashenlin Pharm Grp Co Ltd SHG:603233	Biotechnology	0.02%
Staidson Beijing Biopharma SHE:300204	Biotechnology	7.93%
Tibet Cheezheng Tibetan Medicine Co Ltd SHE:002287	Biotechnology	41.25%
Ardelyx Inc NASDAQ:ARDX	Biotechnology	41.14%
Xiangxue Pharmaceutical SHE:300147	Biotechnology	0.05%

Annual Asset Resilience Ratio for Shanghai Hile Bio-tech (2015–2024)

The table below shows the annual Asset Resilience Ratio data for Shanghai Hile Bio-tech.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	8.68%	CN¥158.58 Million ≈ $23.21 Million	CN¥1.83 Billion ≈ $267.32 Million	-4.14pp
2023-12-31	12.82%	CN¥212.48 Million ≈ $31.09 Million	CN¥1.66 Billion ≈ $242.58 Million	-2.78pp
2022-12-31	15.60%	CN¥236.15 Million ≈ $34.56 Million	CN¥1.51 Billion ≈ $221.58 Million	-5.31pp
2021-12-31	20.91%	CN¥385.59 Million ≈ $56.42 Million	CN¥1.84 Billion ≈ $269.85 Million	-7.23pp
2020-12-31	28.14%	CN¥502.73 Million ≈ $73.57 Million	CN¥1.79 Billion ≈ $261.46 Million	-3.84pp
2019-12-31	31.98%	CN¥544.00 Million ≈ $79.60 Million	CN¥1.70 Billion ≈ $248.95 Million	+8.00pp
2018-12-31	23.98%	CN¥419.24 Million ≈ $61.35 Million	CN¥1.75 Billion ≈ $255.87 Million	-11.96pp
2017-12-31	35.94%	CN¥575.66 Million ≈ $84.24 Million	CN¥1.60 Billion ≈ $234.38 Million	+4.11pp
2016-12-31	31.83%	CN¥471.00 Million ≈ $68.92 Million	CN¥1.48 Billion ≈ $216.56 Million	+8.36pp
2015-12-31	23.46%	CN¥291.00 Million ≈ $42.58 Million	CN¥1.24 Billion ≈ $181.50 Million	--

pp = percentage points

About Shanghai Hile Bio-tech

SHG:603718 China Biotechnology

Market Cap

$372.04 Million

CN¥2.54 Billion CNY

Market Cap Rank

#14027 Global

#4410 in China

Share Price

CN¥3.90

Change (1 day)

+0.00%

52-Week Range

CN¥3.85 - CN¥7.73

All Time High

CN¥51.09